Comparative Pharmacology
Head-to-head clinical analysis: ERY TAB versus ERYTHROMYCIN ESTOLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERY TAB versus ERYTHROMYCIN ESTOLATE.
ERY-TAB vs ERYTHROMYCIN ESTOLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation step.
Erythromycin estolate is a macrolide antibiotic that reversibly binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation step. It may also exhibit immunomodulatory and anti-inflammatory effects.
250-500 mg orally every 6 hours or 333-666 mg every 8 hours. Maximum 4 g/day.
250-500 mg orally every 6-12 hours
None Documented
None Documented
The terminal elimination half-life of erythromycin base is approximately 1.5-2 hours in patients with normal renal function. In patients with end-stage renal disease, the half-life may be prolonged to 4-6 hours. The half-life is not significantly altered in hepatic impairment, but accumulation can occur with severe liver disease.
Approximately 1.5-2 hours in normal adults; prolonged to 5-6 hours in end-stage renal disease.
Erythromycin is primarily excreted in bile as active drug and metabolites, with approximately 12-15% of an administered dose excreted unchanged in urine. Fecal elimination accounts for about 30-60% of the dose, largely due to biliary excretion.
Primarily hepatic via biliary excretion into feces; approximately 2-5% excreted unchanged in urine. <5% renal elimination.
Category C
Category A/B
Macrolide Antibiotic
Macrolide Antibiotic